ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease…
February 22, 2026 16:00 ET | Source: Dyne Therapeutics, Inc. - Late-breaking poster to feature new positive cardiopulmonary function results…